FAK Inhibitor GSK2256098

Phase 2Small molecule

AAlliance for Clinical Trials in Oncology

FAK Inhibitor GSK2256098 is one of 43 small molecule programs targeting Intracranial Meningioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracranial MeningiomaRecruiting

MeningiomaActive, not recruiting

Intracranial MeningiomaPhase 2

Recruiting

MeningiomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

54 competitors in Meningioma

#DrugCompanyPhaseTrials

Cyklokapron

AAmring

Approved

2 2

Epsom Salt

FFresenius Kabi Oncology Ltd.

Signifor

Mifeprex

1 5

Gleevec

Novartis

Phase 2

3 6

Afinitor

Novartis

Phase 2

2 7

Keytruda

Merck & Co.

Phase 2

2 8

Sutent

Pfizer

Phase 2

1 9

Stivarga

Bayer

Phase 2

1 10

Cabometyx

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Intracranial Meningioma

NCT02523014

Clinical

Trials by Indication[1]

Intracranial Meningioma1 trial

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT02523014·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FAK Inhibitor GSK2256098. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FAK Inhibitor GSK2256098 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FAK Inhibitor GSK2256098. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alliance for Clinical Trials in Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlliance for Clinical Trials in Oncology

FAK Inhibitor GSK2256098

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Intracranial Meningioma1 trial

References

Drug Info

Quick Facts

Related News